Umicore targets 30% market share in platinum APIs

Published: 19-Oct-2009
Ingredients

Umicore, a developer of metal based APIs for the pharmaceutical industry, has built a US$10m platinum based API plant in Buenos Aires, Argentina in an effort to improve quality and become a market leader in platinum APIs.


Umicore, a developer of metal based APIs for the pharmaceutical industry, has built a US$10m platinum based API plant in Buenos Aires, Argentina in an effort to improve quality and become a market leader in platinum APIs.

The GMP-approved plant became fully operational earlier this year and uses the company's precious metal chemistry expertise to produce platinum APIs for oncology products.

Umicore currently enjoys a 30% market share in Latin America with its Cis-Platin, Carbo-Platin and Oxali-Platin compounds.

"The capacity of the new plant allows us to supply 50% of the worldwide demand," says Matthias Grehl, Umicore's business line manager. "We target a 30% market share in platinum APIs by 2015."

Grehl says Umicore is also in talks with partners to develop "new, maybe gold-based" products at the Buenos Aires plant in the future.

  • Companies:
  • Umicore Group
See more

You may also like

Media

Brenntag North America announces collaboration with Umicore

Read more
The partnership will focus on the distribution of polyurethane and polyester catalysts

Trending Articles

  1. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  2. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  3. The evolution of the pharma industry: From reactive to disruptive Globally, the pharma industry has witnessed waves of changes during the last century; we have evolved, writes Ajit Kanetkar, Head, Process Technology, ACG, from maintaining a conservative outlook and being solely reactive to disease and healthcare issues to having a radical and disruptive approach
  4. Highly potent APIs: Hazards in classification and handling This variability and subjective nature of classification means that the OEL is best considered as a tool for site risk management teams
  5. Rousselot announces access to pure gelatins through BIO INX Research and technical grade gelatins are now available for online purchase in Canada, Europe, South Korea and the US

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Media

Brenntag North America announces collaboration with Umicore

The partnership will focus on the distribution of polyurethane and polyester catalysts
Ingredients

Umicore receives world first CEP-certificate for zinc oxide

EDQM grants Umicore the world’s first CEP-Certificate of Suitability for zinc oxide
Ingredients

Umicore’s Argentinian facility for anticancer APIs passes first European cGMP audit

Materials group has been making further improvements to the plant in Pilar, Buenos Aires
Ingredients

SiliCycle to distribute Umicore's precious metal-based catalysts in North America

<p>Canada-based SiliCycle, a fine chemistry company specialising in silica-based products, is to sell Belgium-based Umicore\'s precious metal-based homogenous catalysts to the North American life science industry.</p>
Manufacturing

CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery

The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
Ingredients

Therapeutic: acoramidis for transthyretin amyloid cardiomyopathy

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare progressive disease that results from genetic mutations or ageing; misfolded TTR protein accumulates as amyloid fibrils in the myocardium
Ingredients

Therapeutic: lutikizumab for hidradenitis suppurativa

Hidradenitis suppurativa (HS) — also known as acne inversa — is a chronic, recurrent and progressive inflammatory disease that leads to irreversible skin damage and disability
Subscribe now